UNICHEM LABORATORIES LTD. - 506690 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Pradeep BhandariDesignation :- Company Secretary and Compliance Officer UNICHEM LABORATORIES LTD. - 506690 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Equity Intelligence India Pvt Ltd UNICHEM LABORATORIES LTD. - 506690 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under regulation 74[5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2021. 
Unichem Labs surges 15% on ANDA nod from USFDA for Aripiprazole tablets
Aripiprazole tablets are indicated for Schizophrenia and Irritability associated with Autistic Disorder UNICHEM LABORATORIES LTD. - 506690 - ANDA Approval For Aripiprazole Tablets
ANDA approval for Aripiprazole Tablets
Unichem Laboratories climbs 19% after ICRA reaffirms long-term rating
The share touched its 52-week high of Rs 374.90 and 52-week low of Rs 197.50 on May 21, 2021 and November 22, 2021, respectively. Unichem Laboratories Ltd - 506690 - Announcement under Regulation 30 (LODR)-Credit Rating
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ICRA Rating - assigned credit rating for Rs. 176 crs (increased from Rs. 146 crs to Rs. 176 crs) Unichem Laboratories Ltd - 506690 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Financial Results for the second quarter and six months ended September 30, 2021 published in newspapers on November 3, 2021. UNICHEM LABORATORIES LTD. - 506690 - Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Six Months Ended 30.9.2021
Unaudited financial results (Standalone and Consolidated) for the second quarter and six months ended 30.9.2021